Market closed
Altimmune/$ALT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Altimmune
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Ticker
$ALT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
59
Website
Altimmune Metrics
BasicAdvanced
$398M
-
-$1.34
0.86
-
Price and volume
Market cap
$398M
Beta
0.86
52-week high
$9.50
52-week low
$3.55
Average daily volume
2.6M
Financial strength
Current ratio
13.112
Quick ratio
12.897
Long term debt to equity
1.135
Total debt to equity
1.361
Interest coverage (TTM)
-11,463.56%
Management effectiveness
Return on assets (TTM)
-36.85%
Return on equity (TTM)
-59.86%
Valuation
Price to revenue (TTM)
18,398.577
Price to book
3.03
Price to tangible book (TTM)
3.03
Price to free cash flow (TTM)
-4.597
Growth
Revenue change (TTM)
-95.31%
Earnings per share change (TTM)
-19.40%
3-year revenue growth (CAGR)
-83.45%
3-year earnings per share growth (CAGR)
-17.12%
What the Analysts think about Altimmune
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Altimmune stock.
Altimmune Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Altimmune Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Altimmune News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Altimmune stock?
Altimmune (ALT) has a market cap of $398M as of April 26, 2025.
What is the P/E ratio for Altimmune stock?
The price to earnings (P/E) ratio for Altimmune (ALT) stock is 0 as of April 26, 2025.
Does Altimmune stock pay dividends?
No, Altimmune (ALT) stock does not pay dividends to its shareholders as of April 26, 2025.
When is the next Altimmune dividend payment date?
Altimmune (ALT) stock does not pay dividends to its shareholders.
What is the beta indicator for Altimmune?
Altimmune (ALT) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.